These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 18413641)

  • 41. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
    Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
    Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
    Chamberlain MC; Glantz MJ
    Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A
    Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
    Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review.
    Ayash LJ; Clarke M; Silver SM; Braun T; Uberti J; Ratanatharathorn V; Reynolds C; Ferrara J; Broun ER; Adams PT
    Bone Marrow Transplant; 2001 May; 27(9):939-47. PubMed ID: 11436104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [High-dose chemotherapy in relapse of medulloblastoma in young children].
    Dupuis-Girod S; Hartmann O; Benhamou E; Doz F; Mechinaud F; Bouffet E; Coze C; Kalifa C
    Bull Cancer; 1997 Mar; 84(3):264-72. PubMed ID: 9207872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
    Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
    Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
    El-Helw LM; Naik JD; Chester JD; Joffe JK; Selby PJ; Coleman RE
    BJU Int; 2006 Sep; 98(3):519-25. PubMed ID: 16925746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
    Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH
    Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
    Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
    Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
    Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
    Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line autologous stem cell transplantation in primary CNS lymphoma.
    Brevet M; Garidi R; Gruson B; Royer B; Vaida I; Damaj G
    Eur J Haematol; 2005 Oct; 75(4):288-92. PubMed ID: 16146534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
    Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.